Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S.

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...

The FDA has approved Tryptyr (acoltremon) as the first TRPM8-targeting eye drop for dry eye disease, stimulating natural tear ...

The FDA approved Tryptyr to treat the signs and symptoms of dry eye disease, according to a press release from Alcon. Tryptyr ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

The tear film coating the eye offers a window into a person's systemic and ocular health, carrying biomarkers such as glucose ...

U.S. President Donald Trump speaks next to a portrait of former U.S. President Ronald Reagan during a press conference with Elon Musk (not pictured) in the Oval Office of the White House, in ...

The risk of systemic side effects is greater in infants than in adults due to increased percutaneous drug absorption and lower blood volume. The closed eyes technique of eyedrop administration is ...